WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2000059886) BENZIMIDAZOLE ABD IMIDAZOLOPHYRIDINE DERIVATIES, THEIR PREPARATION AND THEIR USE AS SELECTIVE MODULATORS OF BRADYKININ B2 (=BK-2) RECEPTORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2000/059886    International Application No.:    PCT/US2000/008568
Publication Date: 12.10.2000 International Filing Date: 31.03.2000
Chapter 2 Demand Filed:    01.11.2000    
IPC:
C07D 471/04 (2006.01)
Applicants: NEUROGEN CORPORATION [US/US]; 35 Northeast Industrial Road, Branford, CT 06405 (US) (For All Designated States Except US).
DESIMONE, Robert, W. [US/US]; (US) (For US Only).
HUTCHISON, Alan [US/US]; (US) (For US Only).
SHAW, Kenneth [US/US]; (US) (For US Only).
MAYNARD, George, D. [US/US]; (US) (For US Only).
PETERSON, John, M. [US/US]; (US) (For US Only).
LEW, Richard [US/US]; (US) (For US Only).
BRIELMANN, Harry, L. [US/US]; (US) (For US Only)
Inventors: DESIMONE, Robert, W.; (US).
HUTCHISON, Alan; (US).
SHAW, Kenneth; (US).
MAYNARD, George, D.; (US).
PETERSON, John, M.; (US).
LEW, Richard; (US).
BRIELMANN, Harry, L.; (US)
Agent: DOCTER, Stephen, H.; McDonnell Boehnen Hulbert & Berghoff, Suite 3200, 300 South Wacker Drive, Chicago, IL 60606 (US)
Priority Data:
60/127,505 02.04.1999 US
09/285,327 02.04.1999 US
Title (EN) BENZIMIDAZOLE ABD IMIDAZOLOPHYRIDINE DERIVATIES, THEIR PREPARATION AND THEIR USE AS SELECTIVE MODULATORS OF BRADYKININ B2 (=BK-2) RECEPTORS
(FR) DERIVES AMINOALKYLIMIDAZOLE FUSIONNES ARYLE ET HETEROARYLE: MODULATEURS SELECTIFS DE RECEPTEURS DE BRADYKININE B¿2?
Abstract: front page image
(EN)Disclosed are compounds of formula (I) or pharmaceutically acceptable salts thereof wherein: R¿1? is not 3-fluorobenzyl and represents (C¿2?-C¿6?) alkenyl, aryl (C¿1?-C¿6?)alkyl or heteroaryl (C¿1?-C¿6?)alkyl, OR¿7?, O(CH¿2?)¿n?C(O)R¿7?, O(CH¿2?)¿n?NR¿7?R¿8?, O(CH¿2?)¿n?CO¿2?R¿7?, NR¿7?COR¿8?, COR¿7?, CONR¿7?R¿8? or CO¿2?R¿7?; R¿2? represents hydrogen, hydroxy, halogen, trifluoromethyl, trifluoromethoxy, amino (C¿1?-C¿6?)alkyl, mono- or di(C¿1?-C¿6?)alkylamino (C¿1?-C¿6?), or mono- or di(C¿1?-C¿6?)alkylamino(C¿1?-C¿6?)alkoxy; or OR¿7?, O(CH¿2?)¿n?C(O)R¿7?, O(CH¿2?)¿n?NR¿7?R¿8?, O(CH¿2?)¿n?CO¿2?R¿7?, NR¿7?COR¿8?, COR¿7?, CONR¿7?R¿8? or CO¿2?R¿7?; R¿3? represents (C¿1?-C¿6?)alkyl; R¿4? represents halogen or trifluoromethyl; R¿5? and R¿6? represent hydrogen, trifluoromethyl, triluoromethoxy, cyano, (C¿1?-C¿6?)alkyl, halogen, (C¿1?-C¿6?)alkylamino(C¿1?-C¿6?)alkyl, mono or di(C¿1?-C¿6?)alkylamino(C¿1?-C¿6?), or mono- or di(C¿1?-C¿6?)alkylamino(C¿1?-C¿6?)alkoxy; or together form a 5 or 6 membered aromatic ring which is optionally substituted. X represents a bond or CH¿2? which is optionally mono- or disubstituted with a (C¿1?-C¿6?)alkyl or (C¿1?-C¿6?)alkoxy; and A, B, C and D are the same or different and represent CR¿p? or N with the proviso that not more than two of A,B, C and D represent N; which compounds are selective modulators of Bradykinin B¿2? receptors.
(FR)la présente invention concerne des composés de formule (I) ou des sels non toxiques pharmaceutiquement acceptables de ceux-ci. Dans cette formule A, B, C, et D sont N or CH; X est une liaison ou CH¿2? substitué ou non substitué; R¿1? est alcényle inférieur ou alkyle inférieur éventuellement substitué; R¿1? est alkyle inférieur; et R¿2?, R¿4?, R¿5?, et R¿6? sont des variables définies. Ces composés conviennent pour le diagnostic et le traitement de maladies rénales, pour des dysfonctionnements cardiaques, l'hypertension, la maladie de Ménière, les douleurs et les inflammations vaginales, les troubles de la circulation périphérique, les troubles climatériques, les troubles de la circulations rétinochoroïdienne, l'ischémie myocardique, l'infarctus du myocarde, le syndrome de Dressler, l'angine de poitrine, la resténose suite à angioplastie transluminale coronaire percutanée, l'hépatite, la cirrhose du foie, la pancréatite, les occlusions intestinales, le diabète, les complications diabétiques, l'infertilité masculine ou le glaucome, ou pour augmenter la perméabilité de la barrière hémato-encéphalique, pour les douleurs, l'asthme et les rhinites..
Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)